Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors

NCT06266299 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.

NCT NCT06266299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06266299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors
Lead sponsor
Kyowa Kirin Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 18, 2024
Completion date
March 31, 2029
Enrollment
101 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, metastatic solid tumor, non small cell lung cancer